Opinion

Video

Exploring Oral Systemic Therapies For Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Author(s):

Lauren Miller, MPAS, PA-C,Jayme M Heim, MSN, FNP-BC

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Related Videos
Duloxetine for Patients with COPD Suffering from Comorbid Depression
Enhancing Standards for Ethical Responsibilities within Clinical Research
Jennifer Flemming, MD | Credit: AASLD
Related Content
FDA Accepts Plozasiran NDA for Familial Chylomicronemia Syndrome | Image Credit: US Food and Drug Administration
January 20th 2025

FDA Accepts Plozasiran NDA for Familial Chylomicronemia Syndrome

Connor Iapoce
Default thumbnail for The Medical Sisterhood podcast
January 16th 2025

Medical Sisterhood: Polished and Powerful—Women Leading the Charge in Advocacy

Mona Shahriari, MD, FAAD Shadi Kourosh, MD, MPH
Joselyn Rojas-Quintero, MSc, MD | Credit: American Lung Association
January 20th 2025

Metabolic Reprograming in Alveolar Epithelial Cells Type 2: Repurposing Old Drugs for Emphysema Treatment

Joselyn Rojas-Quintero, MD
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes | Image Credit: HCPLive
January 16th 2025

Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Technology

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Denise A. Kent, PhD | Credit: American Lung Association
January 20th 2025

Ethical Excellence: Returning Computed tomography rEsults to actIVE Lung Health Cohort participants (RECEIVE)

Denise Kent, PhD, APRN
ONS-5010 for Wet AMD Secures Noninferiority in NORSE EIGHT Trial | Image Credit: Wills Eye Hospital
January 19th 2025

ONS-5010 for Wet AMD Secures Noninferiority in NORSE EIGHT Trial

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.